SMYD3 and carcinoma: These data were consistent with a previous finding that SMYD3 could activate MAP kinase signaling through methylating MAP3K2 and promote the formation of Ras-driven carcinomas [59] and remodel the tumor microenvironment by activation of MEK/ERK [60].